Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership on May 17, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.94 CNY | +2.94% | +4.52% | -8.10% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.10% | 615M | |
+31.75% | 690B | |
+25.44% | 546B | |
-4.83% | 358B | |
+16.57% | 323B | |
+5.01% | 287B | |
+14.57% | 235B | |
+5.34% | 199B | |
-9.90% | 195B | |
+4.70% | 161B |
- Stock Market
- Equities
- 603520 Stock
- News Zhejiang Starry Pharmaceutical Co.,Ltd.
- Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.